Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 43% Below Their Intrinsic Value Estimate
Today we will run through one way of estimating the intrinsic value of Amarin Corporation plc ( NASDAQ:AMRN ) by taking...
Simply Wall St. · 2d ago
Amarin outlines marketing strategy for Vazkepa in Europe
Following the EU approval for Vazkepa (icosapent ethyl) to treat high-risk cardiovascular patients, Amarin Corporation ([[AMRN]] -1.7%) today updated on its plans for the commercial launch of the treatment in the region.The
Seekingalpha · 4d ago
Amarin Unveils Commercial Initiatives in Europe for VAZKEPA Drug
MT Newswires · 4d ago
MT Newswires · 4d ago
MT Newswires · 4d ago
BRIEF-Amarin Starts Commercial Initiatives For Vazkepa In European Union Following Recent Regulatory Approval For Cardiovascular Risk Reduction Indication · 5d ago
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
DUBLIN, Ireland and BRIDGEWATER, Apr 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- Reimbursement dossiers for first 10 countries to be filed in coming months 150...
GlobeNewswire · 5d ago
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Benzinga · 03/30 13:06
Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl
Benzinga · 03/30 12:16
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
Amarin wins EU approval for icosapent ethyl to treat cardiovascular patients
Amarin Corporation (AMRN) has added ~4.9% in the pre-market after announcing that the European Commission has approved its marketing application for Vazkepa (icosapent ethyl) to treat high-risk cardiovascular patients.Vazkepa is now indicated to reduce
Seekingalpha · 03/30 11:42
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in REDUCE-IT® 1, 2 DUBLIN, Ireland and BRIDGEWATER, ...
GlobeNewswire · 03/30 11:24
Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl
Benzinga · 03/30 11:16
UPDATE 1-European Commission clears Amarin's fish-oil derived heart drug Vazkepa · 03/30 10:54
BRIEF-Amarin Receives European Commission (Ec) Approval For Vazkepa To Reduce Cardiovascular Risk · 03/30 10:41
Amarin's heart drug Vazkepa gets European Commission approval · 03/30 10:32
Amarin Gets European Regulator's Approval For Cardiovascular Disease Drug Vazkepa
MT Newswires · 03/30 07:08
Amarin PLC Stock Appears To Be Possible Value Trap
GuruFocus News · 03/29 20:12
Amarin announces clinical recommendations for Vascepa in Canada and Egypt
Amarin Corporation ([[AMRN]] +1.3%) has announced two new recommendations for its lead product Vascepa (icosapent ethyl) in Canada and Egypt.Vascepa is now included in the 2021 Canadian Cardiovascular Society Guidelines and Egyptian
Seekingalpha · 03/29 14:33
Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases
HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included icosapent ethyl (Vascepa) in 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults, published in the Canadian Journal of Car...
Benzinga · 03/29 12:28
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.